# Title
LUMEN COMPANY INSIGHT: QUIDELORTHO REPORTS STRONG Q1 RESULTS

# Summary
1. Event Recognition

QuidelOrtho (NASDAQ: QDEL) reported its financial results for Q1 of FY 2025:
- Revenue: $692.8 million, slightly above analysts' expectations of $689.8 million, despite a year-on-year decrease of 2.6%.
- Adjusted EPS: $0.74, exceeding analysts' expectations of $0.59 by 25%.
- Adjusted EBITDA: $159.8 million, surpassing analysts' expectations of $149.4 million, with a profit margin of 23.1%.
- Annual revenue guidance: The company reaffirmed its full-year revenue expectation at $2.71 billion, in line with market expectations.
- Annual EPS guidance: Expected adjusted EPS of $2.32, median in line with market expectations.
- Annual EBITDA guidance: Expected EBITDA of $595 million, consistent with market forecasts.
- Operating profit margin: 4.7%, a significant improvement from -247% in the same period last year.
- Constant currency revenue: Decreased by 1.1%, compared to -15.5% last year.
- Market capitalization: $1.75 billion.

# News Comment
1. Event Recognition

QuidelOrtho (NASDAQ: QDEL) reported its financial results for Q1 of FY 2025:
- Revenue: $692.8 million, slightly above analysts' expectations of $689.8 million, despite a year-on-year decrease of 2.6%.
- Adjusted EPS: $0.74, exceeding analysts' expectations of $0.59 by 25%.
- Adjusted EBITDA: $159.8 million, surpassing analysts' expectations of $149.4 million, with a profit margin of 23.1%.
- Annual revenue guidance: The company reaffirmed its full-year revenue expectation at $2.71 billion, in line with market expectations.
- Annual EPS guidance: Expected adjusted EPS of $2.32, median in line with market expectations.
- Annual EBITDA guidance: Expected EBITDA of $595 million, consistent with market forecasts.
- Operating profit margin: 4.7%, a significant improvement from -247% in the same period last year.
- Constant currency revenue: Decreased by 1.1%, compared to -15.5% last year.
- Market capitalization: $1.75 billion.

2. Motivation Analysis

QuidelOrtho's revenue performance this quarter met market expectations. Despite a slight year-on-year decrease of 2.6%, adjusted EPS and EBITDA exceeded expectations, demonstrating growth advantages in cost control and market share. Notably, the operating profit margin rebounded from -247% to 4.7%, highlighting improved operational efficiency and cost management. Additionally, the guidance for full-year revenue, EPS, and EBITDA was not lowered, indicating management's confidence in future growth.

3. Structural Perspective

QuidelOrtho focuses on medical diagnostics and IVD products, including lab tests and home rapid tests. Despite a slight revenue decline, the profit structure has significantly improved, with an operating profit margin turning positive at 4.7%, reflecting successful internal cost control strategies. The decrease in constant currency revenue to just 1.1% indicates effective management of currency impacts in international business. Overall, the financial structure appears more robust, especially with adjusted EBITDA exceeding market expectations by 7%.

4. Key Variables
- Growth in the lab testing market: Sustained demand in lab testing is crucial for future revenue.
- Operational efficiency and cost control: Continued margin improvement will drive long-term growth.
- Currency impacts in international markets: Stabilization of constant currency revenues will be key.
- Technology and product updates: Maintaining a competitive edge in the fast-evolving IVD market is vital for market share.

5. Trend Forecast

If QuidelOrtho continues optimizing cost management and expands its lab testing and rapid testing products, EBITDA and operating profit margins are likely to grow. Furthermore, alleviating currency risks in international markets will aid in restoring revenue growth. The stable demand in the medical diagnostics market and the introduction of new products will be the main drivers of future growth.

LUMEN Structural Analysis

QuidelOrtho's financial results reflect structural growth improvement. Although revenue has slightly declined, cost control and recovering profit margins show enhanced internal management efficiency. From LUMEN's perspective, core structural optimization is evident in robust growth in the lab testing business and improved operational efficiency. Structural analysis suggests the company is recovering from previously high operating costs, with expanded market share and profit margins. Continued enhancement of stability in international markets and product technology updates will strengthen its growth trajectory.
